Sarah Frederick represents clients in complex product liability mass torts, antitrust multi-district litigation and putative class actions, and challenges to agency actions at the trial and appellate levels. She has considerable experience in the pharmaceutical industry, including the statutory and regulatory framework governing prescription pharmaceuticals.




Ms. Frederick devotes much of her practice to representing pharmaceutical clients in complex products liability mass torts and antitrust putative class actions, particularly those that require specialized knowledge of the regulatory framework for the prescription pharmaceutical industry. Ms. Frederick also practices regularly before state and federal appellate courts. Her significant matters include:

  • Serves on National Defense Team for Leading Manufacturer Defending Pharmaceutical Mass Torts
    Secured a number of dismissals on the basis of federal preemption, including in the U.S. Supreme Court case of PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), and before the Eleventh Circuit in Guarino v. Wyeth, LLC, 719 F.3d 1245 (11th  Cir. 2013). Significant experience litigating before state coordinated proceedings in California, New Jersey, Pennsylvania, Missouri, and Massachusetts.
  • Defends Leading Pharmaceutical Manufacturer in Putative Class Actions Challenging Patent Litigation Settlements
    Currently defending client in putative class actions challenging patent litigation settlements on antitrust grounds, initiated after the Supreme Court’s decision in FTC v. Actavis, 133 S. Ct. 2223 (2013).
  • Protects Interests of Pharmaceutical Companies in Agency Actions
    Achieved victory for NDA holder in the face of a challenge to the FDA’s approval of its cutting-edge 505(b)(2) drug application. Protected interests of ANDA holders in retaining regulatory approval for the introduction of the first generic versions of drugs.
  • Regularly Practices Before State and Federal Appellate Courts
    Obtained reversal of adverse judgment on behalf of financial institution client in Vazquez-Robles v. CommoLoCo, Inc., 757 F.3d 1 (1st Cir. 2014). Drafted petition for certiorari to the U.S. Supreme Court on the breadth of immunity provided to financial institutions for Suspicious Activity Reporting. Drafted amicus brief on behalf of DRI – The Voice of the Defense Bar in Mutual Pharmaceutical Co. v. Bartlett, 133 S. Ct. 2466 (2013), available here.
  • Secured Release of Pro Bono Client From Wrongful Imprisonment
    Represented client in post-conviction proceedings, including in a three-day evidentiary hearing on third-party guilt. Obtained an order vacating his conviction, and represented him successfully through the State’s appeal of that decision and his release from prison.


While attending law school, Ms. Frederick served as Executive Articles Editor for the North Carolina Law Review. Ms. Frederick was also inducted into the Order of the Coif.

In The News

In den Nachrichten






University of North Carolina School of Law
Duke University


U.S. Court of Appeals for the District of Columbia Circuit, Honorable David B. Sentelle



District of Columbia
North Carolina


U.S. Court of Appeals for the District of Columbia Circuit
U.S. Court of Appeals for the First Circuit
U.S. Court of Appeals for the Third Circuit
U.S. Court of Appeals for the Eleventh Circuit
U.S. District Court for the District of Massachusetts
U.S. District Court for the District of Columbia
U.S. Supreme Court
Get In Touch
In Kontakt kommen
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers
Suche Andere Rechtsanwälte